Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449240 | 0.86 | EPHX1 (0.52) | EPHX1HPGDGPR119ALDH1A1MEN1 | |
| SCHEMBL5450775 | 0.83 | EPHX1 (0.47) | EPHX1HPGDGPR119USP30ALDH1A1 | |
| SCHEMBL5197039 | 0.83 | KMT2A (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL2953243 | 0.81 | EPHX1 (0.58) | EPHX1HPGDGPR119USP30MEN1 | |
| SCHEMBL5457336 | 0.81 | EPHX1 (0.52) | EPHX1HPGDGPR119ALDH1A1MEN1 | |
| SCHEMBL4644042 | 0.81 | EPHX1 (0.52) | EPHX1HPGDGPR119USP30ALDH1A1 | |
| SCHEMBL23111271 | 0.80 | GPR119 (0.51) | EPHX1HPGDGPR119ALDH1A1 | |
| SCHEMBL5195466 | 0.80 | EPHX1 (0.46) | EPHX1HPGDGPR119MEN1KMT2A | |
| SCHEMBL18429019 | 0.79 | GPR119 (0.47) | EPHX1HPGDGPR119 | |
| SCHEMBL18429026 | 0.79 | GPR119 (0.51) | EPHX1HPGDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MC4R, MC5R, TAAR5 | EPHX1 1945/4885HPGD 1226/4885GPR119 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.